Do peptide serums actually regrow edges? What the science says
Quick answer
The creator attributes visible edge regrowth to 6 weeks of topical application of The Ordinary Multi-Peptide Serum, which contains GHK-Cu among other actives. GHK-Cu has shown follicle-stimulating activity in preclinical models, but human clinical trial data specifically for traction alopecia at the hairline remains limited. Edge thinning in this demographic is most commonly traction-related, and addressing mechanical tension on the follicle is a necessary component of any effective intervention.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @afua.kyei actually say?
Honestly, the transcript here is nearly empty. The creator's actual spoken words, "I'm going to do a little bit of this," repeated three times, give us almost nothing to fact-check directly. The real claims live in the caption: six weeks of The Ordinary Peptide Serum, visible edge regrowth, and enough confidence to stop "gatekeeping" it. That's what we're working with.
To be fair to the creator, they're not claiming a cure. They're sharing a personal before-and-after experience with a commercially available topical serum. That's a meaningful distinction. But 48,000 views means a lot of people are now considering this product as a hair restoration solution, so the underlying biology deserves a real look.
Does the science back this up?
Weakly, and only for one specific ingredient. The Ordinary Multi-Peptide Serum for Hair Density contains several actives, but the one with the most relevant research for hair is GHK-Cu, a copper peptide. This is where things get interesting.
GHK-Cu has shown real biological activity in hair follicle research. Uno et al. (1999, Journal of Dermatological Science) found that copper peptides stimulated hair follicle enlargement and prolonged the anagen (growth) phase in animal models. A later in vitro study by Pickart et al. (2015, Journal of Aging Science) linked GHK-Cu to increased hair follicle proliferation signals. These are not nothing results.
However, traction alopecia, which is what edge thinning typically is in Black women, involves mechanical follicle damage over time. The evidence that topical peptides can reverse established follicle miniaturization in humans, specifically at the hairline, through six weeks of topical application alone, is thin. Animal models and cell cultures do not automatically translate to your edges.
What did they get wrong (or right)?
They got the enthusiasm right, and the price point is genuinely accessible compared to clinical alternatives. But there are a few things worth flagging.
- Six weeks is short. Hair growth cycles run 2 to 6 years. The anagen phase alone averages 3 years. Visible changes at 6 weeks could reflect reduced breakage, improved scalp moisture, or simply better styling practices, not new follicle activity. It's nearly impossible to confirm new growth versus retained length in that window without trichoscopy.
- The root cause matters. If edge thinning is from traction (tight styles, extensions, or edges laid with heavy gels repeatedly), no peptide serum addresses the mechanical stress that caused the damage. Stopping the source of tension is the first intervention, not a serum.
- GHK-Cu is real, but the dose and delivery are unknown. The Ordinary does not publish the concentration of GHK-Cu in this product. Absorption of peptides through intact scalp skin is limited. The gap between in vitro efficacy and what reaches a follicle through topical application remains a legitimate open question.
What should you actually know?
Edge thinning, particularly in Black women, is a recognized clinical pattern often linked to traction alopecia, and it can become permanent if follicles are lost entirely. The good news is that early-stage traction alopecia is reversible. The less good news is that reversing it usually requires more than a serum.
Minoxidil remains the only topically applied ingredient with robust, replicated clinical trial data for hairline and edge regrowth. Low-level laser therapy has moderate evidence. Platelet-rich plasma injections have growing support. Topical peptide serums like this one are biologically plausible but are not in the same evidence tier.
If you are genuinely concerned about edge thinning, a dermatologist or trichologist can use dermoscopy to assess whether follicles are still viable. That assessment changes everything about what interventions actually make sense for your specific situation. A $12 serum is not a substitute for knowing whether your follicles are still there to be stimulated.
The bottom line on peptides and hair
GHK-Cu is one of the more legitimate peptides in the hair growth conversation. It is not a fringe ingredient. But "biologically interesting" and "clinically proven to regrow thinning edges in 6 weeks" are very different claims. The creator's personal experience is real to them. It may not be replicable for someone with more advanced follicle damage, a different cause of thinning, or a different hair care routine. Take the result seriously as a data point, not as a prescription.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Do peptide serums actually regrow edges? What the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Do peptide serums actually regrow edges? What the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator attributes visible edge regrowth to 6 weeks of topical application of The Ordinary Multi-Peptide Serum, which contains GHK-Cu among other actives.
FormBlends verdict
The creator attributes visible edge regrowth to 6 weeks of topical application of The Ordinary Multi-Peptide Serum, which contains GHK-Cu among other actives. GHK-Cu has shown follicle-stimulating activity in preclinical models, but human clinical trial data specifically for traction alopecia at the hairline remains limited. Edge thinning in this demographic is most commonly traction-related, and addressing mechanical tension on the follicle is a necessary component of any effective intervention.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator attributes visible edge regrowth to 6 weeks of topical application of The Ordinary Multi-Peptide Serum, which contains GHK-Cu among other actives. GHK-Cu has shown follicle-stimulating activity in preclinical models, but human clinical trial data specifically for traction alopecia at the hairline remains limited. Edge thinning in this demographic is most commonly traction-related, and addressing mechanical tension on the follicle is a necessary component of any effective intervention.
- GHK-Cu, the copper peptide in The Ordinary's serum, has shown follicle-stimulating effects in preclinical models (Uno et al., 1999, Journal of Dermatological Science), but human trial data for traction alopecia specifically is limited.
- 6 weeks is too short a window to confirm new follicle growth, as opposed to reduced breakage. Most clinical hair studies use 16 to 24-week minimum observation periods.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GHK-Cu, the copper peptide in The Ordinary's serum, has shown follicle-stimulating effects in preclinical models (Uno et al., 1999, Journal of Dermatological Science), but human trial data for traction alopecia specifically is limited.
- 6 weeks is too short a window to confirm new follicle growth, as opposed to reduced breakage. Most clinical hair studies use 16 to 24-week minimum observation periods.
- Traction alopecia, the most common cause of edge thinning in Black women, requires removing the source of mechanical tension first. No topical peptide addresses that root cause.
- Minoxidil is the only topically applied compound with replicated, FDA-reviewed clinical evidence for hairline regrowth. Peptide serums are not in the same evidence category.
- If follicle miniaturization has advanced to fibrosis, topical interventions including peptides are unlikely to restore growth. Dermoscopy or trichoscopy by a dermatologist can determine whether follicles are still viable.
- The Ordinary does not publish the concentration of GHK-Cu in this product, and transdermal peptide absorption through intact scalp skin is limited, making efficacy claims difficult to evaluate.
- Personal testimonials with 48K views carry real influence, but individual results are shaped by cause of hair loss, stage of follicle damage, and concurrent habits that no single product controls.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
F · TikTok creator
48.3K views on this video
No filter, full transparency, just me growing back my edges!! I’ve been using “the ordinary peptide serum” for 6 weeks now and I actually see the difference guys, I was gonna gatekeep so the price doesn’t increase, but everyone deserves edges 😂😂 I always wanna try cecred but this so far has impressed me, I will continue to update yall 💙💙 #growbackedges #edgesthinning #hairlinerestoration #hairgrowthjourney #hairupdate
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by F, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.